NASDAQ:ALPN Alpine Immune Sciences (ALPN) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$64.97▼$64.9750-Day Range$64.37▼$64.9752-Week Range$8.33▼$65.00Volume1,200 shsAverage Volume1.92 million shsMarket Capitalization$4.46 billionP/E RatioN/ADividend YieldN/APrice Target$52.33 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Alpine Immune Sciences alerts: Email Address Alpine Immune Sciences MarketRank™ Stock AnalysisAnalyst RatingHold2.27 Rating ScoreUpside/Downside19.5% Downside$52.33 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$1,227 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.74) to ($1.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.43 out of 5 starsMedical Sector843rd out of 879 stocksPharmaceutical Preparations Industry398th out of 417 stocks 2.1 Analyst's Opinion Consensus RatingAlpine Immune Sciences has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 3 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageAlpine Immune Sciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alpine Immune Sciences' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ALPN. Previous Next 0.0 Dividend Strength Dividend YieldAlpine Immune Sciences does not currently pay a dividend.Dividend GrowthAlpine Immune Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALPN. Previous Next 0.6 News and Social Media Coverage Search Interest2 people have searched for ALPN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Alpine Immune Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alpine Immune Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,227.00 in company stock.Percentage Held by Insiders42.30% of the stock of Alpine Immune Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.17% of the stock of Alpine Immune Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alpine Immune Sciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alpine Immune Sciences are expected to decrease in the coming year, from ($1.74) to ($1.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alpine Immune Sciences is -101.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alpine Immune Sciences is -101.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlpine Immune Sciences has a P/B Ratio of 13.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alpine Immune Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Oasis GoldNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! About Alpine Immune Sciences Stock (NASDAQ:ALPN)Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.Read More Ad Oasis GoldNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! ALPN Stock News HeadlinesMay 16, 2024 | markets.businessinsider.comWhat 11 Analyst Ratings Have To Say About Alpine Immune SciencesMay 10, 2024 | investorplace.comALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q1 2024July 8, 2024 | Oasis Gold (Ad)New Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.May 9, 2024 | businesswire.comAlpine Immune Sciences Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comVertex Pharmaceuticals Inc (VRTX) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...May 1, 2024 | morningstar.comAlpine Immune Sciences IncApril 27, 2024 | benzinga.comLatest News for Alpine Immune Sciences Stock (NASDAQ:ALPN)April 27, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune ...July 8, 2024 | Oasis Gold (Ad)New Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.April 26, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPNApril 23, 2024 | finance.yahoo.comAlpine Immune Sciences, Inc. (ALPN)April 18, 2024 | msn.comTD Cowen Downgrades Alpine Immune Sciences (ALPN)April 17, 2024 | prnewswire.comINVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPNApril 17, 2024 | msn.comAlpine Immune Sciences (ALPN) Price Target Increased by 36.91% to 63.24April 15, 2024 | investorplace.comCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?April 13, 2024 | fool.comCould This Stock Be the Next Biotech Buyout?April 12, 2024 | stockhouse.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Alpine Immune Sciences, Inc. BuyoutApril 12, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPNSee More Headlines Receive ALPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/07/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALPN CUSIPN/A CIK1626199 Webwww.alpineimmunesciences.com Phone(206) 788-4545Fax303-440-8399Employees142Year FoundedN/APrice Target and Rating Average Stock Price Target$52.33 High Stock Price Target$65.00 Low Stock Price Target$18.00 Potential Upside/Downside-19.5%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,180,000.00 Net Margins-65.17% Pretax Margin-64.99% Return on Equity-14.86% Return on Assets-11.82% Debt Debt-to-Equity RatioN/A Current Ratio9.56 Quick Ratio9.56 Sales & Book Value Annual Sales$56.52 million Price / Sales78.85 Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book13.40Miscellaneous Outstanding Shares68,598,000Free Float39,581,000Market Cap$4.46 billion OptionableOptionable Beta0.97 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Mitchell H. Gold M.D. (Age 56)Executive Chairman & CEO Comp: $778.2kDr. Stanford Peng M.D. (Age 53)Ph.D., President and Head of Research & Development Comp: $751.2kMr. Paul Rickey (Age 45)Senior VP, CFO, Treasurer & Secretary Comp: $577.1kMs. M. Christina Yi (Age 47)Chief Technology Officer Temre JohnsonHead of IR & Corporate CommunicationsDr. Remy Durand Ph.D. (Age 39)Chief Business Officer Dr. Wolfgang Dummer M.D. (Age 58)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsFive Prime TherapeuticsNASDAQ:FPRXXencorNASDAQ:XNCRZymeworksNYSE:ZYMEHarpoon TherapeuticsNASDAQ:HARPMacroGenicsNASDAQ:MGNXView All CompetitorsInsiders & InstitutionsLynx1 Capital Management LPSold 1,560,743 shares on 5/30/2024Ownership: 3.285%Boston PartnersBought 23,101 shares on 5/28/2024Ownership: 0.034%Farallon Capital Management LLCBought 5,900 shares on 5/24/2024Ownership: 0.009%Virtu Financial LLCBought 14,813 shares on 5/20/2024Ownership: 0.022%Artal Group S.A.Bought 355,025 shares on 5/17/2024Ownership: 0.592%View All Insider TransactionsView All Institutional Transactions ALPN Stock Analysis - Frequently Asked Questions How were Alpine Immune Sciences' earnings last quarter? Alpine Immune Sciences, Inc. (NASDAQ:ALPN) released its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.15. The biotechnology company earned $7.03 million during the quarter, compared to the consensus estimate of $5.50 million. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 14.86% and a negative net margin of 65.17%. What other stocks do shareholders of Alpine Immune Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA) and OPKO Health (OPK). This page (NASDAQ:ALPN) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpine Immune Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alpine Immune Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
